These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 15271107)

  • 1. Determinants of prescribing patterns for type II diabetes at Primary Care Trust level.
    Lloyd DC; Scrivener G
    J Clin Pharm Ther; 2004 Aug; 29(4):389-94. PubMed ID: 15271107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Race, ethnicity, and use of thiazolidinediones among US adults with diabetes.
    Aquilante CL; Zhang W; McCollum M
    Curr Med Res Opin; 2007 Mar; 23(3):489-94. PubMed ID: 17355730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinediones and slowing the progression of diabetes.
    Jackson T; Aquilina A; Bloom J; Guerra-Garcia H; Salom I; Tzeel A; Kaminsky R
    Manag Care Interface; 2007 Aug; 20(8):29-34. PubMed ID: 18041348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The increase in the use of drug treatment for diabetes mellitus in the Netherlands, 1998-2003].
    Langendam MW; Hooijkaas C; Piepenbrink JF
    Ned Tijdschr Geneeskd; 2006 Jun; 150(25):1396-401. PubMed ID: 16841589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of patients with type 2 diabetes mellitus with pioglitazone. A survey of a Cochrane review].
    Madsbad S
    Ugeskr Laeger; 2007 Nov; 169(47):4054-7. PubMed ID: 18078659
    [No Abstract]   [Full Text] [Related]  

  • 6. Oral combination therapy with thiazolidinediones and sulfonylureas in type 2 diabetes.
    Charbonnel B
    Int J Clin Pract Suppl; 2007 Jun; (153):1-2. PubMed ID: 17594387
    [No Abstract]   [Full Text] [Related]  

  • 7. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.
    Hedblad B; Zambanini A; Nilsson P; Janzon L; Berglund G
    J Intern Med; 2007 Mar; 261(3):293-305. PubMed ID: 17305652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point: Recent long-term clinical studies support an enhanced role for thiazolidinediones in the management of type 2 diabetes.
    Kahn SE; Zinman B
    Diabetes Care; 2007 Jun; 30(6):1672-6. PubMed ID: 17351271
    [No Abstract]   [Full Text] [Related]  

  • 9. Distal upper and lower limb fractures associated with thiazolidinedione use.
    Jones SG; Momin SR; Good MW; Shea TK; Patric K
    Am J Manag Care; 2009 Aug; 15(8):491-6. PubMed ID: 19670952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.
    Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
    Clin Ther; 2007 Jun; 29(6 Pt 1):1306-15. PubMed ID: 18036392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 2 diabetes, psoriasis and thiazolidinediones.
    Krentz AJ; Friedmann PS
    Int J Clin Pract; 2006 Mar; 60(3):362-3. PubMed ID: 16494655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
    Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
    Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vertebral fractures in males with type 2 diabetes treated with rosiglitazone.
    Mancini T; Mazziotti G; Doga M; Carpinteri R; Simetovic N; Vescovi PP; Giustina A
    Bone; 2009 Oct; 45(4):784-8. PubMed ID: 19527806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple oral therapy for type 2 diabetes.
    Bell DS
    Diabetes Res Clin Pract; 2007 Dec; 78(3):313-5. PubMed ID: 17320237
    [No Abstract]   [Full Text] [Related]  

  • 15. [Consulting Prof. Dr. Stephan Matthaei. Quakenbrück diabetes center. Prescription relevant conclusions].
    Matthaei S
    MMW Fortschr Med; 2007 Apr; 149(15):53. PubMed ID: 17668779
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment satisfaction of diabetic patients: what are the contributing factors?
    Biderman A; Noff E; Harris SB; Friedman N; Levy A
    Fam Pract; 2009 Apr; 26(2):102-8. PubMed ID: 19254969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Explaining variation in antidepressant prescribing rates in east London: a cross sectional study.
    Hull SA; Aquino P; Cotter S
    Fam Pract; 2005 Feb; 22(1):37-42. PubMed ID: 15640295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes.
    Donnelly R
    Int J Clin Pract; 2007 Jul; 61(7):1160-9. PubMed ID: 17511791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling lifetime metabolic progression and cost effectiveness of treatment strategies for type 2 diabetes.
    Palmer AJ; Currie CJ
    Pharmacoeconomics; 2006; 24(9):927-9; author reply 929-35. PubMed ID: 16942126
    [No Abstract]   [Full Text] [Related]  

  • 20. The potentially inappropriate prescription of new drug: thiazolidinediones for patients with type II diabetes in Taiwan.
    Wen YW; Tsai YW; Huang WF; Hsiao FY; Chen PF
    Pharmacoepidemiol Drug Saf; 2011 Jan; 20(1):20-9. PubMed ID: 21182151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.